ALPMY - Pfizer Astellas amend procols on prostate cancer trials August, 22 2018 07:01 PM Astellas Pharma Inc. ADR Pfizer (NYSE:PFE) and partner Astellas Pharma (OTCPK:ALPMY) has amended the clinical research protocols for two trials of enzalutamide, accelerating primary completion dates on both. More news on: Pfizer Inc., Astellas Pharma, Inc. ADR, Astellas Pharma, Inc., Healthcare stocks news, Read more ...